Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
- CHF | -.--% |
|
-.--% | -.--% |
Omzet 2024 * | 6,41 mln. 5,73 mln. 6 mln. | Omzet 2025 * | 7,39 mln. 6,6 mln. 6,92 mln. | Marktkapitalisatie | 15,15 mln. 13,52 mln. 14,17 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -72 mln. -64,29 mln. -67,35 mln. | Nettowinst (verlies) 2025 * | -44 mln. -39,29 mln. -41,16 mln. | EV/omzet 2024 * | 5,71 x |
Nettoschuld 2024 * | 21,5 mln. 19,2 mln. 20,11 mln. | Nettoschuld 2025 * | 78,9 mln. 70,45 mln. 73,8 mln. | EV/omzet 2025 * | 12,7 x |
K/w-verhouding 2024 * |
-0,22
x | K/w-verhouding 2025 * |
-0,38
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 84,75% |
Recentste transcriptie over Cara Therapeutics, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 54 | 06-08-18 | |
Ryan Maynard
DFI | Director of Finance/CFO | 54 | 12-09-22 |
Scott Terrillion
CMP | Compliance Officer | 61 | 01-11-16 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Martin Vogelbaum
CHM | Chairman | 60 | 01-07-10 |
Jeffrey Ives
BRD | Director/Board Member | 73 | 16-07-14 |
Helen Boudreau
BRD | Director/Board Member | 58 | 02-08-23 |
![Consensus](/images/consensus_flch.gif)
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+2,22% | 93,91 mld. | |
-1,32% | 38,4 mld. | |
-13,44% | 32,61 mld. | |
+76,30% | 28,2 mld. | |
-13,11% | 15,91 mld. | |
+0,68% | 14,22 mld. | |
-12,06% | 11,54 mld. | |
+185,28% | 10,74 mld. | |
-53,00% | 9,47 mld. |
- Beurs
- Aandelen
- Koers CARA
- Koers 69C